Is Pimitespib the NB003 targeted drug?

Pimitespib is not the same drug as other targeted drugs on the market named NB003. There are significant differences between the two in molecular structure, target mechanism and indication development direction. In some Chinese medical forums or overseas drug purchasing channels, NB003 is sometimes generally referred to as a heat shock protein 90 (HSP90) inhibitor, so it may be mistaken for an alias of pimetibib, but in fact they represent different drug candidates.

NB003 is more commonly used as the name of pipelines under development by certain biopharmaceutical companies in China, and does not appear widely in international registered drug databases. According to public information, NB003 may be an experimental targeted drug that is still in the preclinical or early clinical stage and has not yet received formal marketing approval from any major regulatory agency. At the same time, pimetibib, as a mature HSP90 inhibitor successfully promoted and completed phase III research by Japan's Taiho Company, has a complete trade name (Jeselhy) and approved clinical indications (gastrointestinal stromal tumor). It is currently one of the few commercialized products in the HSP90 field.

The reason why the two are easily confused may be because they have overlap in treatment targets (HSP90), and both are used to explore solid tumor treatments, but the drug development progress and corporate background are completely different. In order to accurately identify the source of drugs, it is recommended that patients and medical staff strictly refer to the International System for Nomenclature of Drugs (INN) or official databases such as FDA, EMA, PMDA, etc. for confirmation.

To sum up, pimetibi is not a targeted drugNB003. It is an HSP90 inhibitor that has been approved for marketing and has complete drug registration information and marketing name Jeselhy; while NB003 may be other drug candidates in the development stage. The two cannot be understood interchangeably, nor are they equivalent. For clinical medication and drug purchase consultation, avoid using the development code as a reference for drug purchase to prevent potential safety hazards caused by mistaken purchase or misuse.

Reference materials:https://en.wikipedia.org/wiki/Pimitespib